IL- 21 and Immune Mediated Viral Control
IL-21 和免疫介导的病毒控制
基本信息
- 批准号:7802289
- 负责人:
- 金额:$ 47.06万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2009
- 资助国家:美国
- 起止时间:2009-05-01 至 2014-04-30
- 项目状态:已结题
- 来源:
- 关键词:AcuteAntibody FormationB-LymphocytesCD4 Positive T LymphocytesCD8B1 geneCellsChronicDefectDependencyDevelopmentGenerationsHelper-Inducer T-LymphocyteHeterogeneityHumanImmuneImmunityImmunologic MemoryInfectionInfection ControlLifeLongevityMediatingPlayRoleShapesSignal TransductionSourceT cell responseT memory cellT-LymphocyteT-Lymphocyte SubsetsTherapeuticTherapeutic EffectViralVirus Diseasesbasecombatexhaustionfunctional disabilityresponse
项目摘要
DESCRIPTION (provided by applicant): Developing an in-depth understanding of the factors that regulate the induction, quality, and longevity of anti- viral T cell responses is essential for devising rational strategies to combat viral infections. A hallmark of robust anti-viral immunity is the elaboration of potent CD4 and CD8 T cell responses which act cooperatively to bring about control of the infection. The consequences of ineffective responses can be catastrophic, resulting in viral persistence or the loss of long-lived immunological memory. Nevertheless, the signals which drive the development of the most robust polyfunctional effector responses and dictate the emergence of memory T cells are not fully understood. The purpose of this proposal is to capitalize on compelling preliminary findings which indicate that IL-21 plays a vital role in anti-viral immunity. Our initial studies clearly show that without sufficient levels of IL-21 the generation of polyfunctional effector CD8 T cells is compromised, and quite strikingly T cell exhaustion is exacerbated during chronic infections. Significantly, many of the phenotypic and functional impairments in anti-viral CDS T cells which manifest in the absence of IL-21 resemble the defects observed in CD4 T cell deficient hosts. A principal producer of IL-21 are CD4 follicular helper cells (Tfh) which function to help antibody responses, therefore Tfh derived IL-21 may be the critical factor that helps CD8 T cell responses. It is, however, unclear whether IL-21 is acting directly or indirectly on anti-viral CD8 T cells to promote their functionality, how T cell heterogeneity is shaped by IL-21, whether Tfh are the essential cellular sources of IL-21, and whether IL-21 based treatments have therapeutic benefits on viral control both during acute and chronic infection. We therefore propose the following specific aims: 1). Determine the direct effects of IL-21 on polyfunctional anti-viral CDS T cells. 2). Elucidate the role of CD4 T cell-derived IL-21 in promoting anti-viral immunity. 3). Define the significance of IL-21-producing CD4 T cells during viral infections of humans 4). Determine the therapeutic effects of IL-21 on anti-viral immunity and control.
描述(由申请人提供):深入了解调节抗病毒T细胞反应的诱导、质量和寿命的因素对于设计合理的策略来对抗病毒感染至关重要。强大的抗病毒免疫的一个标志是有效的CD4和CD8 T细胞反应的阐述,它们协同作用以控制感染。无效反应的后果可能是灾难性的,导致病毒持续存在或长期免疫记忆的丧失。然而,驱动最强大的多功能效应反应的发展和指示记忆T细胞出现的信号尚未完全了解。本提案的目的是利用令人信服的初步发现,表明IL-21在抗病毒免疫中起着至关重要的作用。我们的初步研究清楚地表明,如果没有足够水平的IL-21,多功能效应CD8 T细胞的产生就会受到损害,并且在慢性感染期间,T细胞衰竭会明显加剧。值得注意的是,在缺乏IL-21的情况下,抗病毒CDS T细胞的许多表型和功能损伤类似于在CD4 T细胞缺陷宿主中观察到的缺陷。IL-21的主要生产者是CD4滤泡辅助细胞(Tfh),其功能是帮助抗体反应,因此Tfh衍生的IL-21可能是帮助CD8 T细胞反应的关键因素。然而,目前尚不清楚IL-21是否直接或间接作用于抗病毒CD8 T细胞以促进其功能,IL-21如何塑造T细胞异质性,Tfh是否是IL-21的基本细胞来源,以及基于IL-21的治疗是否在急性和慢性感染期间对病毒控制具有治疗益处。因此,我们提出以下具体目标:1)。确定IL-21对多功能抗病毒CDS T细胞的直接作用。2). 阐明CD4 T细胞来源的IL-21在促进抗病毒免疫中的作用。3). 确定在人类病毒感染过程中产生il -21的CD4 T细胞的意义4)。确定IL-21对抗病毒免疫和控制的治疗效果。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Allan J Zajac其他文献
Allan J Zajac的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Allan J Zajac', 18)}}的其他基金
The Regulation of T Cell Exhaustion by Adhesion Molecules
粘附分子对 T 细胞耗竭的调节
- 批准号:
8290753 - 财政年份:2012
- 资助金额:
$ 47.06万 - 项目类别:
The Regulation of T Cell Exhaustion by Adhesion Molecules
粘附分子对 T 细胞耗竭的调节
- 批准号:
8416362 - 财政年份:2012
- 资助金额:
$ 47.06万 - 项目类别:
相似海外基金
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9981001 - 财政年份:2017
- 资助金额:
$ 47.06万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9751102 - 财政年份:2017
- 资助金额:
$ 47.06万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
9397073 - 财政年份:2017
- 资助金额:
$ 47.06万 - 项目类别:
Characterization of Naturally Occurring Anti-Blood Group Antibody Formation
天然存在的抗血型抗体形成的表征
- 批准号:
10223410 - 财政年份:2017
- 资助金额:
$ 47.06万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-BETA (REBI
使用 SC IFN-β (REBI) 预防 MS 患者中和抗体形成
- 批准号:
7951676 - 财政年份:2008
- 资助金额:
$ 47.06万 - 项目类别:
PREVENTING NEUTRALIZING ANTIBODY FORMATION IN MS PATIENTS WITH SC IFN-β-AL
预防 SC IFN- 多发性硬化症患者中和抗体的形成
- 批准号:
7606036 - 财政年份:2006
- 资助金额:
$ 47.06万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7375053 - 财政年份:2005
- 资助金额:
$ 47.06万 - 项目类别:
IMMUNOLOGIC MECHANISM OF INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA
血友病抑制剂抗体形成的免疫学机制
- 批准号:
7201220 - 财政年份:2004
- 资助金额:
$ 47.06万 - 项目类别:
Immunologic Mechanism of Inhibitor Antibody Formation in Hemophilia
血友病抑制剂抗体形成的免疫学机制
- 批准号:
6980810 - 财政年份:2003
- 资助金额:
$ 47.06万 - 项目类别:
INHIBITOR ANTIBODY FORMATION IN HEMOPHILIA AND VON WILLEBRAND'S DISEASE
血友病和冯·维勒布兰德病中的抑制剂抗体形成
- 批准号:
6419444 - 财政年份:2000
- 资助金额:
$ 47.06万 - 项目类别:














{{item.name}}会员




